Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
about
Vitamin D compounds for people with chronic kidney disease requiring dialysisHyperphosphatemia Management in Patients with Chronic Kidney DiseaseInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemVitamin D and kidney transplant outcomes: a protocol for a systematic review and meta-analysisAre there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathyTreatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.Pharmacotherapy of end-stage renal disease.Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients.Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.Vitamin d receptor activators and clinical outcomes in chronic kidney disease.Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.Mortality rates do not differ among patients prescribed various vitamin D agents.Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.Paricalcitol for secondary hyperparathyroidism in renal transplantation.A new paradigm for the treatment of secondary hyperparathyroidism.Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients.The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism.Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients.A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forwardParicalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT studyBudget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital.Current treatment options in secondary renal hyperparathyroidism.Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy.Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea.Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs.Doxercalciferol treatment of secondary hyperparathyroidism.A bimodal association of vitamin D levels and vascular disease in children on dialysisImpact of activated vitamin D and race on survival among hemodialysis patients.Vitamin D receptor activators can protect against vascular calcification.Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.Vascular calcification in chronic kidney disease: Pathogenesis and clinical implicationCalcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?Lowering vascular calcification burden in chronic kidney disease: Is it possible?
P2860
Q24240582-DA3CC5EE-B02C-4140-B6C3-31C20ED85238Q26743842-B1F7D0B9-25A4-47F8-A62A-7AFDC35FE874Q26822500-6F70CD9D-3532-4706-8D82-FB7A2CD7E396Q26849676-FE0E2E67-102F-4BF7-B3F3-1CAC30E71D88Q27002431-5A26C1C7-C42D-41CD-BD66-06382D35F182Q28258849-9E8EC9EA-80CD-4E91-9EDB-394CAD5976D4Q33506544-10DB7544-A2C7-4EF7-9F9C-5E457032DACBQ33531889-537C5D27-C041-4E21-BB0E-6F5C45497F1AQ34483554-F1F07411-21C5-48F7-B037-9E13EB774617Q34491713-C0892D01-E775-4C13-8399-5DD682DB6266Q34621641-F971AFAE-F26B-426B-9809-6645323978C7Q35020986-93DC4DD1-5E75-45A8-83EC-A4F603045142Q35026640-A1769A5F-3AD5-48E0-9917-37010BFCE754Q35106077-93A3FE7C-D9BD-455E-9713-5AFE361C841CQ35188367-24AD2D0B-401E-4D8F-88C5-17FDC7E0D5FEQ35550544-E5931932-8F95-4A40-AC5D-D455218C182FQ35573634-01A3B37D-0423-4B55-B8F8-B589A5502613Q35573639-1B76AF17-6B0C-49D5-9D2E-9FAF5140992CQ35573698-59B73125-8B49-400F-BF2F-FF575C76BE75Q35573785-47F449BB-2268-4ACB-95C7-20C8C6C843BDQ35682192-D57A61B3-26F9-4996-A0C3-E3E1F52A02A2Q35782007-9BD141EE-0F3A-4335-9258-EB84FA166802Q35920190-55FA8FDE-5B5F-4BDB-8FB3-AEA3D6E0A76CQ36114718-293FF958-0815-40DC-BA91-7C8D4A26391DQ36250191-A81DAC65-E78F-4CC1-98C2-FCB807ABE19CQ36345591-0FF809DB-A58F-4971-9643-6806AE1300A8Q36466029-FE267B17-350D-4320-A98F-2F9D0AC34ADFQ36567144-86BE89B3-36E9-4CB8-8146-7FCFF83AAD11Q36613869-AE3D942A-60C0-4AF4-8516-705658D18DF4Q36632228-D0FAB9C6-D2E4-4A0C-AE37-E88C5FA37EA8Q36633869-7C743635-9B5F-4A4C-BEDA-82FA2B10F951Q36677652-99F1034D-39EF-4AF8-BA5C-694DA6F42728Q36736787-F05E4E8E-D941-4E1B-A62D-32908492A788Q36796781-76D0237B-D2B1-4ED6-9F25-BA5B849DFE50Q36947391-6A90B7DC-93AF-4BD6-8335-217C362CC7AAQ37123402-8E43215C-7EEB-46AE-B7FB-2BA23978AE8BQ37162738-3F15524B-601E-4740-BBAC-3BFEF8E85076Q37195354-07A88195-FABE-4AA4-A105-BF1DBFB34D7FQ37310824-B440A674-8E52-47C9-BD8E-20754C76384CQ37322136-06172CC2-92D4-4C16-86E9-ED9431A31896
P2860
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@en
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@nl
type
label
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@en
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@nl
prefLabel
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@en
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@nl
P2093
P1433
P1476
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
@en
P2093
Carol Taccetta
Daniel Batlle
Francisco Llach
Michael Amdahl
Stuart M Sprague
P304
P356
10.1046/J.1523-1755.2003.00878.X
P407
P577
2003-04-01T00:00:00Z
P5875
P6179
1040094515